Enzo Biochem, Inc. (ENZ)
Market Cap | 99.39M |
Revenue (ttm) | 81.12M |
Net Income (ttm) | -35.24M |
Shares Out | 48.72M |
EPS (ttm) | -0.73 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,956,818 |
Open | 2.15 |
Previous Close | 2.24 |
Day's Range | 2.03 - 2.23 |
52-Week Range | 1.00 - 3.09 |
Beta | 0.88 |
Analysts | Buy |
Price Target | n/a |
Earnings Date | Mar 27, 2023 |
About ENZ
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides... [Read more]
Financial Performance
Financial StatementsNews

Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results
- Company entered into an Asset Purchase Agreement for substantially all of the operating assets of the Clinical Labs division

Why Is Enzo Biochem (ENZ) Stock Up 72% Today?
Enzo Biochem (NYSE: ENZ) stock is rocketing higher on Friday after the company agreed to an asset sale with Labcorp (NYSE: LH). That asset sale has Enzo Biochem agreeing to divest its Clinical Labor...

Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp
Significant value unlocked for Enzo shareholders with continued focus on remaining businesses.

Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update
- Enzo Life Sciences reports revenue of $7.1 million and 9% growth in Q1 FY 2023, excluding FX

Enzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12th
Conference Call and Webcast Scheduled for December 13 th , 8:30 AM ET

Enzo Biochem, Inc. Announces Date of Annual Shareholders' Meeting
NEW YORK, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that its Annual Shareholders' M...

Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO
- David Bench resigning to pursue a new career opportunity - - David Bench resigning to pursue a new career opportunity -

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
- Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX

Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th
Conference Call and Webcast Scheduled for October 1 4 , 202 2 , 8 : 3 0 a m ET

Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2
Powered by Enzo's LoopRNA™ ISH technology, a new platform designed for superior sensitivity in detection and visualization of biomarkers in the spatial context of cells and tissues Powered by Enzo's L...

Enzo Biochem to Launch Monkeypox Testing Services this Week
NEW YORK, NY, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that its full-service clinical ...

Enzo Biochem Reports Third Quarter Fiscal 2022 Results and Provides Leadership and Corporate Updates Including Engagement of Jefferies as Financial Advisor
Conference call and live webcast scheduled for tomorrow, Friday, June 10, 2022 at 8:30 am (ET)

UPDATE -- Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th
Conference Call and Webcast Scheduled for June 10, 2022, 8:30 am ET Conference Call and Webcast Scheduled for June 10, 2022, 8:30 am ET

Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th
Conference Call and Webcast Scheduled for June 9, 2022, 4:30 pm ET

Enzo Biochem Adjourns Annual Meeting of Shareholders to Complete Vote on Proposal
Meeting Scheduled for April 8, 2022 at 9:00 AM ET

Enzo Biochem Adjourns Annual Meeting of Shareholders Until April 8, 2022
NEW YORK, NY, April 01, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced its 2021 Annual Meeting of Sha...

Enzo Biochem Appoints David Bench and Kara Cannon to New Executive Management Positions
NEW YORK, NY, March 28, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced two key appointments to its ne...

Enzo Biochem Reports Second Quarter Fiscal 2022 Result and Provides Leadership and Corporate Updates
Conference call and live webcast scheduled for today, Monday, March 14, 2022 at 4:30 pm (ET)

Enzo Biochem to Present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum
NEW YORK, NY, March 10, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Mark...

Enzo Biochem to Report Second Quarter 2022 Financial Results and Business Update on Monday, March 14th
Conference Call and Webcast Scheduled for March 14, 2022, 4:30 pm ET

Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem's Board of Directors
NEW YORK, NY, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointments of Hamid Erfan...

Enzo Biochem Reports First Quarter 2022 Financial Results and Provides Business Update
Conference call and live webcast scheduled for today, Wednesday, December 15, 2021 at 4:30 pm (ET)

Enzo Biochem to Report First Quarter 2022 Financial Results and Business Update on Wednesday, December 15th
Conference Call and Webcast Scheduled for December 15, 2021, 4:30 pm ET

ENZO BIOCHEM REPORTS INDUCEMENT AWARDS TO NEW CHIEF EXECUTIVE OFFICER
NEW YORK, NY, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that on November 8, 2021, it gra...

Bradley L. Radoff Issues Letter to the Independent Directors of Enzo Biochem Regarding Their Unwillingness to Acknowledge or Address Unprecedented Shareholder Unrest
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, who together with his affiliates holds approximately 7.5% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), tod...